Dr. Vu Q. Phan, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of California, Irvine, California College of Medicine (1998)
- Years since graduation
- 28
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 729
Licensed in California since 1999, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1998Medical school: University of California, Irvine, California College of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CA license A70377 (first issued 1999; current) · CA license A070377 (first issued 1999; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Uci Health-Orange Orange, CA
- Memorialcare Long Beach Medical Center Long Beach, CA
- Memorialcare Orange Coast Medical Center Fountain Valley, CA
- St Mary Medical Center Long Beach, CA
- Uci Health-Lakewood Lakewood, CA
Medical groups
- Cancer and Blood Specialty Clinic (18 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 729
- Services billed
- 162,649
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Injection, ferric carboxymaltose, 1 mg | 53,250 | 25 |
| Injection, denosumab, 1 mg | 14,100 | 83 |
| Injection, romosozumab-aqqg, 1 mg | 14,070 | 13 |
| Injection, dexamethasone sodium phosphate, 1 mg | 2,502 | 22 |
| Established patient office or other outpatient visit, 30-39 minutes | 832 | 268 |
| Injection, ondansetron hydrochloride, per 1 mg | 768 | 14 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 650 | 174 |
| Injection of drug or substance under skin or into muscle | 627 | 132 |
| Established patient office or other outpatient visit, 20-29 minutes | 483 | 301 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 419 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Los Alamitos, CA | 212 |
| Letrozole Other prescribers in Los Alamitos, CA | 178 |
| Eliquis (apixaban) Other prescribers in Los Alamitos, CA | 160 |
| Hydroxyurea Other prescribers in Los Alamitos, CA | 73 |
| Ondansetron Hcl Other prescribers in Los Alamitos, CA | 62 |
| Zoledronic Acid | 60 |
| Prednisone Other prescribers in Los Alamitos, CA | 60 |
| Dexamethasone Other prescribers in Los Alamitos, CA | 53 |
| Lenalidomide | 52 |
| Exemestane | 50 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 57 companies reported 297 payments worth $12,548 in total to this clinician.
| Janssen Biotech, Inc. | $3,424 |
|---|---|
| Stemline Therapeutics Inc. | $2,553 |
| AstraZeneca Pharmaceuticals LP | $664 |
| Pfizer Inc. | $460 |
| Celgene Corporation | $420 |
| E.r. Squibb & Sons, L.l.c. | $416 |
| Boston Scientific Corporation | $382 |
| Incyte Corporation | $338 |
| Food and Beverage | $6,847 |
|---|---|
| Consulting Fee | $5,300 |
| Education | $330 |
| Travel and Lodging | $71.44 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Stemline Therapeutics Inc. Dec 15, 2025 | Consulting Fee Orserdu · Oncology | $2,480 |
| Janssen Biotech, Inc. Jun 24, 2025 | Consulting Fee RYBREVANT · Oncology | $1,500 |
| Janssen Biotech, Inc. May 27, 2025 | Consulting Fee | $1,320 |
| Incyte Corporation Oct 3, 2025 | Education | $99.95 |
| Janssen Biotech, Inc. May 6, 2025 | Education DARZALEX; TALVEY; TECVAYLI · Oncology · in-kind | $96.00 |
| Seagen Inc. May 22, 2025 | Education in-kind | $95.95 |
| Janssen Biotech, Inc. Jun 24, 2025 | Travel and Lodging RYBREVANT · Oncology · travel to LAKE BUENA VISTA, FL | $71.44 |
| Amgen Inc. Jul 31, 2025 | Education in-kind | $32.72 |
| Stemline Therapeutics Inc. Dec 4, 2025 | Education Orserdu · Oncology · in-kind | $5.33 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 19 industry-funded studies in 2025, from 8 companies. The companies reported $1,939,794 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastat…
Janssen Research & Development, LLC - A phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non …
AstraZeneca Pharmaceuticals LP - A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06246916 - A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO (Nivolumab) in Subjects With Treatment-Nave Unresectable or Metastatic Melanoma
Amgen Inc. - A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple …
Janssen Research & Development, LLC - A Phase III,Open label,Randomised,Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations,and Whose …
AstraZeneca UK Limited - A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low…
Celgene Corporation - A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple …
Janssen Research & Development, LLC - A randomized phase 3 openlabel study to evaluate SGNB6A compared with docetaxel in adult subjects with previously treated nonsmall cell lung cancer
Pfizer Inc. - A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT06045689
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.